Fig. 7 | Scientific Reports

Fig. 7

From: Multi-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma

Fig. 7

Molecular docking of major active ingredients with key genes. (A) Sitosterol-CDK1. (B) 3’-Methoxyglabridin-CDK1. (C) Sitosterol-CDK2. (D) 3’-Methoxyglabridin-CDK2. (E) Sitosterol-TOP2A. (F) 3’-Methoxyglabridin-TOP2A. (G) Sitosterol-CHEK1. (H) 3’-Methoxyglabridin-CHEK1. (I) Sitosterol-CDC25C. (J) 3’-Methoxyglabridin-CDC25C.

Back to article page